Relevant bibliographies by topics / Hepatitis B virus

Academic literature on the topic 'Hepatitis B virus'

Author: Grafiati
Published: 4 June 2021
Last updated: 31 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Hepatitis B virus.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Hepatitis B virus"

1

Schaefer, Stephan. "Hepatitis B virus taxonomy and hepatitis B virus genotypes." World Journal of Gastroenterology 13, no. 1 (2007): 14. http://dx.doi.org/10.3748/wjg.v13.i1.14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

AYGEN, Bilgehan, Mustafa Kemal ÇELEN, İftihar KÖKSAL, Selma TOSUN, Oğuz KARABAY, Tansu YAMAZHAN, Orhan YILDIZ, Celal AYAZ, and Fehmi TABAK. "The Prevalence and Epidemiological Characteristics of Hepatitis B Virus and Hepatitis C Virus Coinfection in Turkey." Turkiye Klinikleri Journal of Medical Sciences 33, no. 5 (2013): 1245–49. http://dx.doi.org/10.5336/medsci.2012-32319.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Adil, B., O. Fatih, I. Volkan, B. Bora, E. Veysel, K. Koray, K. Cemalettin, I. Burak, and Y. Sezai. "Hepatitis B Virus and Hepatitis D Virus Recurrence in Patients Undergoing Liver Transplantation for Hepatitis B Virus and Hepatitis B Virus Plus Hepatitis D Virus." Transplantation Proceedings 48, no. 6 (July 2016): 2119–23. http://dx.doi.org/10.1016/j.transproceed.2016.02.076.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Godoy, C., S. Sopena, J. Gregori, D. Tabernero, M. Homs, R. Casillas, A. Ruiz, et al. "Hepatitis B virus quasispecies complexity is lower in hepatitis B virus–hepatitis D virus infection than in hepatitis B virus monoinfection." Journal of Hepatology 66, no. 1 (2017): S483—S484. http://dx.doi.org/10.1016/s0168-8278(17)31360-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Nayak, Akshatha P., Insha Firoz, Ravindra Prabhu, Jayanth Nayak, Veena NK, and Megha Nagaraj Nayak. "Development of Immunity to Hepatitis B Virus Following Hepatitis B Vaccination in Hemodialysis Patient." Annals of International Medical and Dental Research 9, no. 2 (April 2023): 20–23. http://dx.doi.org/10.53339/aimdr.2023.9.2.4.

Full text
Abstract:
Background: Hepatitis B infection is common in Dialysis population. Hemodialysis patients have high risk of hepatitis B virus transmission not only due to frequent blood or blood product transmission, decreased response to Hepatitis B vaccine and length on hemodialysis but also due to their immunosuppressed state. Hepatitis B vaccination has the potential to reduce the risk of HBsAg infection in dialysis units. Effective vaccination, blood donor screening, the use of erythropoietin and the isolation of HBV carriers have successfully regulated HBV infection in hemodialysis units (1). This study aims to assess the immunity to HBV the seroconversion of HBsAg infection in hemodialysis unit. This retrospective observational study evaluated serological markers, hepatitis B vaccination status and co morbidities which can affect the immunity levels of patients undergoing hemodialysis. The patient’s data were collected from laboratory investigations and patient record for analysis. Out of 153 CKD-5D patients on maintenance hemodialysis, 39 patients had anti HBs titer <10U/ml, 30 patients had anti HBs titer between 10-100U/ml, 38 patients had anti HBs titer between100-1000 U/ml, 21 patients had anti HBs titer >1000U/ml and 24 patients didn’t check their titer value. Hypertension was the common co morbidity followed by anaemia and diabetes mellitus.
APA, Harvard, Vancouver, ISO, and other styles
6

Genesca, J., R. Jardi, M. Buti, L. Vives, S. Prat, J. I. Esteban, R. Esteban, and J. Guardia. "Hepatitis b virus replication in acute hepatitis B, acute hepatitis B virus-hepatitis delta virus coinfection and acute hepatitis delta superinfection." Hepatology 7, no. 3 (May 1987): 569–72. http://dx.doi.org/10.1002/hep.1840070325.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ganem, Don. "Hepatitis B Virus." Expert Review of Anti-infective Therapy 1, no. 3 (September 2003): 357–58. http://dx.doi.org/10.1586/14787210.1.3.357.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

XIAO, JIANBO, Lei Zhang, XIAOQING CHEN, Ming Xu *, and XINYU JIANG. "HEPATITIS B VIRUS." Professional Medical Journal 14, no. 02 (September 6, 2007): 241–47. http://dx.doi.org/10.29309/tpmj/2007.14.02.4883.

Full text
Abstract:
Dried leaves of Marchantia convoluta are largely used to protect livers,and to treat tumefaction of skins in China. Flavonoids from Marchantia Convoluta (MCF) was one of the mostpotentially effective anti-inflammatory. MCF was studied here for its ability to inhibit the proliferation of 2,2,15 cells(clone cells derived from HepG2 cells that were transected with a plasmid containing HBV, DNA). All concentrations(5,10,20 and 40 :g/ml) of MCF inhibit hepatitis B surface antigen (HbsAg) and hepatitis B E antigen (HbeAg) in thecultured medium released from 2.2.15 cells. Analysis of morphological changes of MCF-treated phase- contrastmicroscope revealed a possible model of action for MCF to inhibit Proliferation of 2.2.15 cells by inducing apoptosis.
APA, Harvard, Vancouver, ISO, and other styles
9

Bredfeldt, James E. "Hepatitis B virus." Postgraduate Medicine 78, no. 6 (November 1985): 71–83. http://dx.doi.org/10.1080/00325481.1985.11699185.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Seitz, R. "Hepatitis B Virus." Transfusion Medicine and Hemotherapy 27, no. 5 (2000): 226–34. http://dx.doi.org/10.1159/000025279.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Hepatitis B virus"

1

Kandpal, Manish. "Role of defective hepatitis B virus in wild-type hepatitis B virus replication." Thesis, IIT Delhi, 2017. http://localhost:8080/xmlui/handle/12345678/7247.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

駱淑芳 and Suk-fong Anna Lok. "Replication of hepatitis B virus in Chinese patients with chronic hepatitis B virus infection." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 1990. http://hub.hku.hk/bib/B31981392.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kidd-Ljunggren, Karin. "Genetic variability in hepatitis B virus." Lund : Depts. of Infectious Diseases and Medical Microbiology, University of Lund, 1995. http://books.google.com/books?id=KDZsAAAAMAAJ.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Umeda, Makoto. "Hepatitis B virus infection in lymphatic tissues in inactive hepatitis B carriers." Kyoto University, 2007. http://hdl.handle.net/2433/135682.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Arauz-Ruiz, Patricia. "Molecular epidemiology of hepatitis A and hepatitis B virus in central America /." Stockholm : Repro Print, 2002. http://diss.kib.ki.se/2002/91-7349-208-6/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Williams, David James. "Hepatitis B virus core gene deletions." Thesis, University of Glasgow, 1997. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.363171.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Williams, Stephen John. "Chronic hepatitis B virus infection : prevention and treatment." Thesis, The University of Sydney, 1989. https://hdl.handle.net/2123/26390.

Full text
Abstract:
Hepatitis B virus (HBV) infection is an increasing public health problem in Australia particularly in certain 'high-risk' subgroups of the population. In order to establish cost-effective screening and vaccination programs directed towards the control and possible eradication of HBV infection, accurate information is needed about the modes of spread and the numbers of "at risk" individuals in particular community subgroups. In addition, treatment strategies must be developed for established HBV carriers since at least 35% of such individuals will die directly related to complications of the disease. This Thesis is the compilation of a series of investigations into familial transmission of chronic HBV infection, the efficacy of alpha interferon treatment of chronic active hepatitis (CAH) B and the effects of such treatment on hepatic drug metabolism. The results have important implications for prevention of HBV infection by screening and vaccination programs, for the selection of patients for inclusion in treatment trials and for the methods by which such treatments can be monitored for responses, and they provide new information about clinically-relevant effects of interferon treatment on the metabolism of other drugs. An overview of the virology of hepatitis B virus (HBV), the biology of HBV infection and the resultant disease states is presented in Chapter 1. In Chapter 2, a prospective study examining the incidence of and factors determining intrafamily HBV transmission in a mixed Caucasian and Asian population is presented. Household contacts of both Asian and Caucasian HBV carriers were clearly demonstrated as being at high-risk for HBV infection. Several factors were identified to be associated with a higher rate of transmission of HBV infection within families; namely, if the index case was Asian rather than Caucasian, had an HBsAg-positive mother rather than an HBsAg-positive father, was HBeAg-positive rather than HBeAg-negative , and had chronic rather than acute HBV infection. In Chapter 3, the first Australian study of alpha interferon (rIFN-aA) in the treatment of CAH-B is reported. While rlFN-aA was demonstrated to have inhibitory effects on HBV replication, the overall response rate was disappointing and not significantly different from the spontaneous seroconversion rate observed in the control group. A major goal of the present study was to establish whether serological changes of HBV infection, that could be induced by interferon, were associated with changes in hepatic function or affected the natural history of this otherwise progressive chronic liver disease. The results provide an important contribution to new knowledge in that although sustained HBV serological improvement was obtained in only 35% of treated patients, this change in the biological state of the virus-host interaction provided a beneficial change in the natural history of chronic liver disease as assessed clinically, biochemically and by direct morphologic examination. In addition, the results presented in Chapter 4 have a novel bearing on whether changes in chronic hepatitis B disease activity improve hepatic metabolic function. Sequential determinations of a simplified 2 point antipyrine clearance (CLAP) test indicated that HBeAg seroconversion was associated consistently with a quantitatively important increase in CLAp while reactivation led to a deterioration in hepatic metabolic function as indicated by the CLAp test. In addition, the CLAp test was a more sensitive and specific indicator of hepatic metabolic function compared to more conventional tests of liver function (serum albumin and bilirubin concentrations, and prothrombin time). Part C describes studies in which the effects of interferon on hepatic drug metabolism have been examined. In human studies in vivo, antipyrine and theophylline were employed as substrates for the cytochrome P-450dependent mixed function oxidase system. The study described in Chapter 6 provides the first direct evidence that interferon inhibits hepatic drug metabolism in humans; a significant reduction in antipyrine clearance was demonstrated following a single intramuscular injection of interferon. In Chapter 7 the clinical relevance of the observed effect of interferon on antipyrine metabolism was confirmed by the demonstration that interferon also impairs theophylline elimination. This demonstrated one of the most profound therapy-induced inhibitions of drug metabolism yet observed in man. In addition, the effect of interferon on hepatic drug metabolism appears to be relatively selective for some cytochrome P-450 isozymes, specifically that concerned with N-demethylation of theophylline. The mechanism for the interferon-mediated impairment of hepatic oxidative drug metabolism observed in the human in vivo studies was then explored by experiments in animals. The isolated perfused rat liver model was utilized to study effects on the intact liver, while hepatic microsomal androstenedione hydroxylation pathways were measured as a probe to assess interferon effects on individual cytochrome P-450 isozymes. The results demonstrated that the effect of IFN on drug metabolism is, at least in rats, species specific. Moreover, the reduction in total hepatic P-450 content produced by lFN appeared to result from a generalized lowering of P-450 isozymes rather than being specific for individual forms. The apparent discrepancy between these findings and the observation in humans that human rlFN-ocA depressed the P-450 isozyme(s) responsible for the Ndemethylation pathway of theophylline metabolism to a greater degree than the 8-hydroxylation pathway may be due to species differences or to the specific types of interferon studied. In any event it is likely that the clearance of many other xenobiotics as well as endogenous substances metabolized by P-450 may be impaired by interferon and future studies should be directed towards examining the effects of interferons on other such clinically-relevant compounds. Moreover, the results of the present study indicate that lFN-treated rats should be a good model with which to obtain clearance data for such compounds.
APA, Harvard, Vancouver, ISO, and other styles
8

Lau, Chi Chiu. "Hepatitis B virus and single nucleotide polymorphisms." HKBU Institutional Repository, 2007. http://repository.hkbu.edu.hk/etd_ra/810.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Taş, Tekin Kaya Selçuk. "Salt anti Hepatit B Virus Core antikoru pozitif kan donörlerinde Hepatit B Virus DNA tespiti /." Isparta : SDÜ Tıp Fakültesi, 2009. http://tez.sdu.edu.tr/Tezler/TT00398.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Luo, Ying. "Hepatitis B virus specific immune response after liver transplantation for chronic hepatitis B /." Click to view the E-thesis via HKUTO, 2006. http://sunzi.lib.hku.hk/hkuto/record/B3697724X.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Hepatitis B virus"

1

Guo, Haitao, and Andrea Cuconati, eds. Hepatitis B Virus. New York, NY: Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-6700-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Guo, Haitao, and Andrea Cuconati, eds. Hepatitis B Virus. New York, NY: Springer US, 2024. http://dx.doi.org/10.1007/978-1-0716-4027-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Tang, Hong, ed. Hepatitis B Virus Infection. Singapore: Springer Singapore, 2020. http://dx.doi.org/10.1007/978-981-13-9151-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Rajen, Koshy, and Caselmann Wolfgang H, eds. Hepatitis B virus: Molecular mechanisms in disease and novel strategies for therapy. London: Imperial College Press, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

1968-, Zhang Weiying, and Ye Lihong, eds. Hepatitis B virus research focus. New York: Nova Science Publishers, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Alan, McLachlan, ed. Molecular biology of the hepatitis B virus. Boca Raton, Fla: CRC Press, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

1946-, Callea F., Zorzi M. 1920-, Desmet V, Associazione volontari italiani del sangue. Brescia Division., and Postgraduate Course on Viral Hepatitis (1985 : Brescia, Italy), eds. Viral hepatitis. Berlin: Springer-Verlag, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

National Digestive Diseases Information Clearinghouse (U.S.), ed. What I need to know about Hepatitis B. Bethesda, Md: Nattional Institutes of Health, National Digestive Diseases Information Clearinghouse, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

National Digestive Diseases Information Clearinghouse (U.S.), ed. Lo que necesito saber sobre la Hepatitis B. Bethesda, Md: Institutos Nacionales De Salud, Centro Coordinador Nacional de Información Sobre las Enfermedades Digestivas, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

National Digestive Diseases Information Clearinghouse (U.S.), ed. Lo que necesito saber sobre la hepatitis B: What I need to know about hepatitis B. [Bethesda, Md.]: U.S. Dept. of Health and Human Services, National Institutes of Health, National Digestive Diseases Information Clearinghouse, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Hepatitis B virus"

1

Vyas, Girish N., and T. S. Benedict Yen. "Hepatitis B Virus." In Viral Hepatitis, 35–63. Totowa, NJ: Humana Press, 1999. http://dx.doi.org/10.1007/978-1-59259-702-4_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Schwab, Manfred. "Hepatitis B Virus." In Encyclopedia of Cancer, 1. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-27841-9_2659-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Bertoletti, Antonio, and Hongming Huang. "Hepatitis B Virus." In Liver Immunology, 255–72. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-51709-0_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Bowden, Scott. "Hepatitis B Virus." In PCR for Clinical Microbiology, 249–52. Dordrecht: Springer Netherlands, 2010. http://dx.doi.org/10.1007/978-90-481-9039-3_36.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

van Balen, J. A. M., A. A. Demeulemeester, M. Frölich, K. Mohrmann, L. M. Harms, W. C. H. van Helden, L. J. Mostert, and J. H. M. Souverijn. "Hepatitis B virus." In Memoboek, 127–28. Houten: Bohn Stafleu van Loghum, 2012. http://dx.doi.org/10.1007/978-90-313-9129-5_68.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Wong, Darren J., Stephen A. Locarnini, and Alexander J. V. Thompson. "Hepatitis B Virus." In Clinical Virology, 713–70. Washington, DC, USA: ASM Press, 2016. http://dx.doi.org/10.1128/9781555819439.ch32.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Lydyard, Peter M., Michael F. Cole, John Holton, William L. Irving, Nina Porakishvili, Pradhib Venkatesan, and Katherine N. Ward. "Hepatitis B virus." In Case Studies in Infectious Disease, 127–35. 2nd ed. Boca Raton: CRC Press, 2023. http://dx.doi.org/10.1201/9781003155447-14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Burman, Blaire E., and Robert S. Brown. "Hepatitis B Virus." In Common Liver Diseases and Transplantation, 79–97. Boca Raton: CRC Press, 2024. http://dx.doi.org/10.1201/9781003523239-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Harrison, Tim J., and Geoffrey M. Dusheiko. "Hepatitis B virus and hepatitis delta virus." In Molecular and Cell Biology of Sexually Transmitted Diseases, 203–32. Dordrecht: Springer Netherlands, 1992. http://dx.doi.org/10.1007/978-94-011-2384-6_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Heath, Ryan D., and Veysel Tahan. "Natural History of Hepatitis B Virus." In Viral Hepatitis: Chronic Hepatitis B, 1–10. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-93449-5_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Hepatitis B virus"

1

Hussain, Hiba T. H., Arwa Mujahid Abdullah Al-Shuwaikh, and Abbas M. Ahmed. "Hepatitis type B virus genotypes in chronic Hepatitis B patients (CHBP)." In 2ND INTERNATIONAL CONFERENCE OF MATHEMATICS, APPLIED SCIENCES, INFORMATION AND COMMUNICATION TECHNOLOGY. AIP Publishing, 2023. http://dx.doi.org/10.1063/5.0162114.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Chanyshev, M. D., N. V. Vlasenko, I. A. Kotov, K. F. Khafizov, and V. G. Akimkin. "HIGH THROUGHPUT DNA SEQUENCING OF HEPATITIS B VIRUS." In X Международная конференция молодых ученых: биоинформатиков, биотехнологов, биофизиков, вирусологов и молекулярных биологов — 2023. Novosibirsk State University, 2023. http://dx.doi.org/10.25205/978-5-4437-1526-1-266.

Full text
Abstract:
It was shown that Hepatitis B Virus (HBV) genotype and individual mutations influence the course of the disease. There is a need for a simple and reliable method for sequencing the entire genome of hepatitis B virus. We have developed an NGS amplification panel for hepatitis B virus genome sequencing. The panel was validated using Sanger sequencing. More than 300 HBV samples were sequenced and genotypes and mutations described in the literature were identified.
APA, Harvard, Vancouver, ISO, and other styles
3

Gür, A., M. Karakoç, MF Geyik, K. Nas, R. Çevik, AJ Saraç, S. Em, and F. Erdogan. "SAT0135 Association between hepatitis c virus antibody, hepatitis b virus antigen and fibromiyalgia." In Annual European Congress of Rheumatology, Annals of the rheumatic diseases ARD July 2001. BMJ Publishing Group Ltd and European League Against Rheumatism, 2001. http://dx.doi.org/10.1136/annrheumdis-2001.594.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Li, Zhi, and Huan Qi. "Identification and Simulation of Hepatitis B Virus Model." In 2010 International Conference on Computational and Information Sciences (ICCIS). IEEE, 2010. http://dx.doi.org/10.1109/iccis.2010.88.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Clemens, R., G. Wirl, C. Velten, and H. J. Röthig. "VIRUS SAFETY OF ANTITHROMBIN III CONCENTRATE KYBERNIN P - APROSPECTIVE CLINICAL TRIAL." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644148.

Full text
Abstract:
In 13 healthy male volunteers a prospective clinical trial was performed to evaluate virus safety of the antithrombin III concentrate Kybernin P in regard to hepatitis B, non-A/non-Band HIV transmission. As the volunteers were participants of a pharmacokinetic study they received either a fixed dosage of 1000 units Kybernin P asbolus injection or a dosage of 50 units per kg body weight as short-term infusion. Two different batches of Kybernin P were used.Whereas in all 13 volunteers virussafety in hepatitis non-A/non-B and HAV transmission could be monitored, only those volunteers who were not vaccinated (n=3) against hepatitis B or who had no protecting antibodies of anti-HB type despite vaccination (n=3)were to be included in the hepatitis B monitoring.All 13 volunteers were followed-upfor 1 year according to the standardsof the International Committee on Thrombosis and Hemostasis (ICTH). For detection of a potential hepatitis non-A/non-B transmission transaminases (AST, ALT) were determined in biweekly intervals during the first 6 months of the observation period and thereafter in monthly intervals. Hepatitis B seromar-kers as well as anti-HIV wereassessed bimonthly. Furthermore, all volunteers were clinically examined at every follow-up.None of the 13 volunteers revealedan increase of transaminases to the 2.5 fold of the upper normal level which is considered to be the borderlinelevel for hepatitis non-A/non-B diagnosis. Furthermore, in none of the volunteers a seroconversion for hepatitis B or HIV could be detected. Thus, Kybernin P is to be considered as hepatitis B, hepatitis non-A/non-B and HIV safe.
APA, Harvard, Vancouver, ISO, and other styles
6

Lukitasari, Lina, Lilik Herawati, Edhi Rianto, Indri Safitri, Retno Handajani, and Soetjpto. "Genotype Hepatitis B Virus Among Intravenous Drug Users with Occult Hepatitis B Infection in Surabaya, Indonesia." In Surabaya International Physiology Seminar. SCITEPRESS - Science and Technology Publications, 2017. http://dx.doi.org/10.5220/0007335401860191.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Long, Changjiang, Huan Qi, and Wan Peng. "System Dynamics of Chronic Hepatitis B - Modeling the Virus and Immune System of Chronic Hepatitis B." In 2010 2nd International Workshop on Intelligent Systems and Applications (ISA). IEEE, 2010. http://dx.doi.org/10.1109/iwisa.2010.5473320.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Evatt, B. L. "VIRUS INACTIVATION AND COAGULATION FACTOR PREPARATIONS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644754.

Full text
Abstract:
Nonheat-treated factor concentrates were used for the therapy of congenital and acquired coagulation deficiencies until 1984. These unheated factor crticentrates, which are manufactured from pooled plasma obtained from between 2500 and 25,000 blood or plasma donors, have been epidemiologically implicated in exposure of large numbers of hemophilia patients to several viral infections Including human immunodeficiency virus (HIV), hepatitis B, and non-A non-B hepatitis. Of these, HIV has been fdund to be very heat labile. After the introduction in 1984-85 of heat treatment of concentrates to reduce the risk of! hepatitis to recipients, several studies documented a lack of HIV serconversion in patients treated with clotting-fadtor concentrates. However, subsequent reports described a few hemophilia patients who had seroconverted to HIV! after receiving heat-treated concentrate from unscreened donors. To determine the significance of these seroconvers(ions, an international survey was conducted on 11 hemophilia treatment centers in Europe, Canada, and the United Kingdcpn whose total patient population comprised more than 2300 hemophilia A patients and 400 hemophilia B patients. Only three patients were found who seroconverted beyond a 6-month period after switching to heat-treated material, a(nd no seroconversions have occurred in these centers between November 1985 and February 1987. In addition no cases of seroconversion on donor screened heat-treated concentrate have been reported since its widespread introduction to the hemophilia patients during 1985-1986. Other modes of viral inactivation are currently being tested, and they appeiar to be effective in inactivating HIV and hepatitis B virus. Some of these methods have shown some promise for the inactivation of non-A and non-B hepatitis, but more data are needed for final assessment of these methods.
APA, Harvard, Vancouver, ISO, and other styles
9

Kipiani, E., M. Butsashvili, G. Kamkamidze, and G. Abashidze. "STUDY OF RISK FACTORS AFFECTING HBV VACCINE EFFICIENCY AMONG CHILDREN IN GEORGIA." In International Trends in Science and Technology. RS Global Sp. z O.O., 2020. http://dx.doi.org/10.31435/rsglobal_conf/30122020/7346.

Full text
Abstract:
In the conditions of mass vaccination of hepatitis B, all over the world, including in Georgia, in the vaccinated population, the numberof those individuals who could not develop Anti-HBs are growing every day. According to the literature, the main reason for the ineffective vaccination of hepatitis B is considered to be an increase in the prevalence of express mutants among the hepatitisB virus population, which is of a similar intensity throughout the world. In parallel with a detailed analysis of literature sources, the scientific article for the first time studied the seroprevalence of Anti-HBs in the population of Georgian vaccinatedchildren.
APA, Harvard, Vancouver, ISO, and other styles
10

Deodato, Raissa, Debora Santos, Helena Cruz, Cristina Lima, Carolina Van der Meer, and Livia Villar. "Usefulness of IgY technology for hepatitis B virus diagnosis." In IV International Symposium on Immunobiologicals & VII Seminário Anual Científico e Tecnológico. Instituto de Tecnologia em Imunobiológicos, 2019. http://dx.doi.org/10.35259/isi.sact.2019_32773.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Hepatitis B virus"

1

Ko, Ping-Hung, Chih-Wei Tseng, and Meng-Hsuan Kuo. The Risk of Hepatitis B Virus Reactivation in Rheumatic Patients Receiving Tocilizumab: A Systematic Review and Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, June 2023. http://dx.doi.org/10.37766/inplasy2023.6.0029.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Long, Siqin, Jiaojian Lv, and Huan Xu. A meta-analysis of the association between type 2 diabetes and hepatocellular carcinoma in patients with hepatitis B virus. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2022. http://dx.doi.org/10.37766/inplasy2022.6.0001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Aierkenjiang, Malipati, Kaidiriya Kuerbanjiang, Hurexitanmu Abudurexiti, Lin Xu, and Xiao Feng Sun. Efficacy and safety of Tenofovir alafenamide in blocking mother-to-child transmission of hepatitis B virus: a meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2022. http://dx.doi.org/10.37766/inplasy2022.11.0061.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Wang, Wanpeng, Shurong Wang, Jia Liu, Yan Liu, Ying Mu, and Jing Wang. Transcatheter hepatic arterial chemoembolization combined with Kangai injection for hepatitis B virus-related hepatocellular carcinoma: protocol for a PRISMA-compliant meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2020. http://dx.doi.org/10.37766/inplasy2020.9.0014.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Xu, Yan, Yuyang Zhao, Yong Wang, Changyu Zhou, Xingang Wang, Yongqiang Dong, and Shaoyou Qin. Concurrent hepatic steatosis increases the risk of hepatocellular carcinoma in patients with chronic hepatitis B or C virus infection: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, July 2020. http://dx.doi.org/10.37766/inplasy2020.7.0099.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Fang, Shengyi, Piao Long, Yuying Yang, Dan Ouyang, and Jianzhong Cao. Clinical efficacy and safety of Traditional Chinese Medicine adjuvant Therapies for hepatitis B virus related Hepatocellular Carcinoma: A protocol for Network Meta-Analysis and Systematic Review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2022. http://dx.doi.org/10.37766/inplasy2022.9.0113.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Li, Ding, Min Zhu, Changhui Zhou, and Xiujing Liu. Effect of Liuweiwuling (LWWL) tablet on biochemical and virological parameters, and quality of life in patients with hepatitis B virus-related cirrhosis: protocol for a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, August 2020. http://dx.doi.org/10.37766/inplasy2020.8.0010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Hajarizadeh, Behzad, Jennifer MacLachlan, Benjamin Cowie, and Gregory J. Dore. Population-level interventions to improve the health outcomes of people living with hepatitis B: an Evidence Check brokered by the Sax Institute for the NSW Ministry of Health, 2022. The Sax Institute, August 2022. http://dx.doi.org/10.57022/pxwj3682.

Full text
Abstract:
Background An estimated 292 million people are living with chronic hepatitis B virus (HBV) infection globally, including 223,000 people in Australia. HBV diagnosis and linkage of people living with HBV to clinical care is suboptimal in Australia, with 27% of people living with HBV undiagnosed and 77% not receiving regular HBV clinical care. This systematic review aimed to characterize population-level interventions implemented to enhance all components of HBV care cascade and analyse the effectiveness of interventions. Review questions Question 1: What population-level interventions, programs or policy approaches have been shown to be effective in reducing the incidence of hepatitis B; and that may not yet be fully rolled out or evaluated in Australia demonstrate early effectiveness, or promise, in reducing the incidence of hepatitis B? Question 2: What population-level interventions and/or programs are effective at reducing disease burden for people in the community with hepatitis B? Methods Four bibliographic databases and 21 grey literature sources were searched. Studies were eligible for inclusion if the study population included people with or at risk of chronic HBV, and the study conducted a population-level interventions to decrease HBV incidence or disease burden or to enhance any components of HBV care cascade (i.e., diagnosis, linkage to care, treatment initiation, adherence to clinical care), or HBV vaccination coverage. Studies published in the past 10 years (since January 2012), with or without comparison groups were eligible for inclusion. Studies conducting an HBV screening intervention were eligible if they reported proportion of people participating in screening, proportion of newly diagnosed HBV (participant was unaware of their HBV status), proportion of people received HBV vaccination following screening, or proportion of participants diagnosed with chronic HBV infection who were linked to HBV clinical care. Studies were excluded if study population was less than 20 participants, intervention included a pharmaceutical intervention or a hospital-based intervention, or study was implemented in limited clinical services. The records were initially screened by title and abstract. The full texts of potentially eligible records were reviewed, and eligible studies were selected for inclusion. For each study included in analysis, the study outcome and corresponding 95% confidence intervals (95%CIs) were calculated. For studies including a comparison group, odds ratio (OR) and corresponding 95%CIs were calculated. Random effect meta-analysis models were used to calculate the pooled study outcome estimates. Stratified analyses were conducted by study setting, study population, and intervention-specific characteristics. Key findings A total of 61 studies were included in the analysis. A large majority of studies (study n=48, 79%) included single-arm studies with no concurrent control, with seven (12%) randomised controlled trials, and six (10%) non-randomised controlled studies. A total of 109 interventions were evaluated in 61 included studies. On-site or outreach HBV screening and linkage to HBV clinical care coordination were the most frequent interventions, conducted in 27 and 26 studies, respectively. Question 1 We found no studies reporting HBV incidence as the study outcome. One study conducted in remote area demonstrated that an intervention including education of pregnant women and training village health volunteers enhanced coverage of HBV birth dose vaccination (93% post-intervention, vs. 81% pre-intervention), but no data of HBV incidence among infants were reported. Question 2 Study outcomes most relevant to the HBV burden for people in the community with HBV included, HBV diagnosis, linkage to HBV care, and HBV vaccination coverage. Among randomised controlled trials aimed at enhancing HBV screening, a meta-analysis was conducted including three studies which implemented an intervention including community face-to-face education focused on HBV and/or liver cancer among migrants from high HBV prevalence areas. This analysis demonstrated a significantly higher HBV testing uptake in intervention groups with the likelihood of HBV testing 3.6 times higher among those participating in education programs compared to the control groups (OR: 3.62, 95% CI 2.72, 4.88). In another analysis, including 25 studies evaluating an intervention to enhance HBV screening, a pooled estimate of 66% of participants received HBV testing following the study intervention (95%CI: 58-75%), with high heterogeneity across studies (range: 17-98%; I-square: 99.9%). A stratified analysis by HBV screening strategy demonstrated that in the studies providing participants with on-site HBV testing, the proportion receiving HBV testing (80%, 95%CI: 72-87%) was significantly higher compared to the studies referring participants to an external site for HBV testing (54%, 95%CI: 37-71%). In the studies implementing an intervention to enhance linkage of people diagnosed with HBV infection to clinical care, the interventions included different components and varied across studies. The most common component was post-test counselling followed by assistance with scheduling clinical appointments, conducted in 52% and 38% of the studies, respectively. In meta-analysis, a pooled estimate of 73% of people with HBV infection were linked to HBV clinical care (95%CI: 64-81%), with high heterogeneity across studies (range: 28-100%; I-square: 99.2%). A stratified analysis by study population demonstrated that in the studies among general population in high prevalence countries, 94% of people (95%CI: 88-100%) who received the study intervention were linked to care, significantly higher than 72% (95%CI: 61-83%) in studies among migrants from high prevalence area living in a country with low prevalence. In 19 studies, HBV vaccination uptake was assessed after an intervention, among which one study assessed birth dose vaccination among infants, one study assessed vaccination in elementary school children and 17 studies assessed vaccination in adults. Among studies assessing adult vaccination, a pooled estimate of 38% (95%CI: 21-56%) of people initiated vaccination, with high heterogeneity across studies (range: 0.5-93%; I square: 99.9%). A stratified analysis by HBV vaccination strategy demonstrated that in the studies providing on-site vaccination, the uptake was 78% (95%CI: 62-94%), significantly higher compared to 27% (95%CI: 13-42%) in studies referring participants to an external site for vaccination. Conclusion This systematic review identified a wide variety of interventions, mostly multi-component interventions, to enhance HBV screening, linkage to HBV clinical care, and HBV vaccination coverage. High heterogeneity was observed in effectiveness of interventions in all three domains of screening, linkage to care, and vaccination. Strategies identified to boost the effectiveness of interventions included providing on-site HBV testing and vaccination (versus referral for testing and vaccination) and including community education focussed on HBV or liver cancer in an HBV screening program. Further studies are needed to evaluate the effectiveness of more novel interventions (e.g., point of care testing) and interventions specifically including Indigenous populations, people who inject drugs, men who have sex with men, and people incarcerated.
APA, Harvard, Vancouver, ISO, and other styles
9

A curriculum guide for public-safety and emergency-response workers. Prevention of transmission of human immunodeficiency virus and hepatitis B virus. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, National Institute for Occupational Safety and Health, February 1989. http://dx.doi.org/10.26616/nioshpub89108.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Hepatitis B virus' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography